XML 18 R4.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Revenues:      
Revenues $ 24,689 $ 22,449 $ 22,127
Costs and expenses:      
Cost of goods sold 4,572 4,675 4,853
Research and development expenses 5,039 4,055 3,920
Acquired in-process research and development expenses 5,856 5,051 1,098
Selling, general and administrative expenses 5,151 4,381 4,056
Total costs and expenses 20,618 18,162 13,927
Income from operations 4,071 4,287 8,200
Interest expense (984) (995) (1,077)
Other income (expense), net (1,418) 1,868 676
Income before income taxes 1,669 5,160 7,799
Income tax expense (benefit) 1,580 (204) 2,339
Net income 89 5,364 5,460
Net (loss) income attributable to noncontrolling interest (34) (22) 5
Net income attributable to Gilead $ 123 $ 5,386 $ 5,455
Net income per share attributable to Gilead common stockholders - basic (usd per share) $ 0.10 $ 4.24 $ 4.20
Shares used in per share calculation - basic (in shares) 1,257 1,270 1,298
Net income per share attributable to Gilead common stockholders - diluted (usd per share) $ 0.10 $ 4.22 $ 4.17
Shares used in per share calculation - diluted (in shares) 1,263 1,277 1,308
Product sales      
Revenues:      
Revenues $ 24,355 $ 22,119 $ 21,677
Royalty, contract and other revenues      
Revenues:      
Revenues $ 334 $ 330 $ 450